DDrare: Database of Drug Development for Rare Diseases

Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-FDG; 68Ga-FAPI; Abatacept; Afucosylated IgG1 kappa monoclonal antibody; Belimumab; Corticosteroids; Device: Mayo Interactive Breath Hold Monitor; Drug free, IS monotherapy and GC combined with IS; Extra blood draw samples; Glucocorticoids; INEBILIZUMAB; Inebilizumab; Leflunomide; Lenalidomide; MONITOR; Methionine; Mycophenolate; Mycophenolate mofetil; Perflubutane; Prednisolone; Prednisone; Prednisone and Belimumab; Prednisone and Mycophenolate mofetil; Procedure: biliary stent; Rilzabrutinib; Rituximab; T 614; Thalidomide; XMAB5871; XmAb5871; Zanubrutinib; Zanubrutinib 80 MG; [XmAb5871]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000028918	2020-01-01	2020-01-07	A randomized, double-blind controlled study of glucocorticoids combination with thalidomide in the treatment of IgG4-related diseases	Efficacy and safety of thalidomide in IgG4-related diseases	IgG4 related disease	control group:prednison combined with placebo;experimental group:prednison combined with thalidomide;	Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	NULL	Recruiting	18	80	Both	control group:51;experimental group:51;	Phase 4	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

ChiCTR2000028918

2020-01-01

2020-01-07

A randomized, double-blind controlled study of glucocorticoids combination with thalidomide in the treatment of IgG4-related diseases

Efficacy and safety of thalidomide in IgG4-related diseases

IgG4 related disease

control group:prednison combined with placebo;experimental group:prednison combined with thalidomide;

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

NULL

Recruiting

Both

control group:51;experimental group:51;

Phase 4

China